{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:44:03Z","timestamp":1788284643795,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Changsha","award":["kq2502051"],"award-info":[{"award-number":["kq2502051"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974080"],"award-info":[{"award-number":["81974080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170640"],"award-info":[{"award-number":["82170640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ30954"],"award-info":[{"award-number":["2022JJ30954"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["2022SK2059"],"award-info":[{"award-number":["2022SK2059"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94401-7","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:54:28Z","timestamp":1742604868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangzhe","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoyun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"94401_CR1","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922. https:\/\/doi.org\/10.1038\/s41591-018-0104-9 (2018).","journal-title":"Nat. Med."},{"key":"94401_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka, A. C. et al. Nonalcoholic steatohepatitis: A review. JAMA 323, 1175\u20131183. https:\/\/doi.org\/10.1001\/jama.2020.2298 (2020).","journal-title":"JAMA"},{"key":"94401_CR3","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41586-022-05299-4","volume":"610","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 610, 562\u2013568. https:\/\/doi.org\/10.1038\/s41586-022-05299-4 (2022).","journal-title":"Nature"},{"key":"94401_CR4","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69, 2672\u20132682. https:\/\/doi.org\/10.1002\/hep.30251 (2019).","journal-title":"Hepatology"},{"key":"94401_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.04.014","author":"S Singh","year":"2015","unstructured":"Singh, S. et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"94401_CR6","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","volume":"158","author":"R Loomba","year":"2020","unstructured":"Loomba, R., Lim, J. K., Patton, H. & El-Serag, H. B. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: Expert review. Gastroenterology 158, 1822\u20131830. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.053 (2020).","journal-title":"Gastroenterology"},{"key":"94401_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","volume":"17","author":"D Ferguson","year":"2021","unstructured":"Ferguson, D. & Finck, B. N. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 484\u2013495. https:\/\/doi.org\/10.1038\/s41574-021-00507-z (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"94401_CR8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005 (2015).","journal-title":"Gastroenterology"},{"key":"94401_CR9","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3 (2021).","journal-title":"Lancet"},{"key":"94401_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan, J. G., Kim, S. U. & Wong, V. W. New trends on obesity and NAFLD in Asia. J. Hepatol. 67, 862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2017.06.003 (2017).","journal-title":"J. Hepatol."},{"key":"94401_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos, S. A., Kountouras, J. & Mantzoros, C. S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 92, 82\u201397. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.014 (2019).","journal-title":"Metabolism"},{"key":"94401_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal, A. J. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 16, 377\u2013386. https:\/\/doi.org\/10.1038\/s41575-019-0144-8 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"94401_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","volume":"1","author":"S Lefere","year":"2019","unstructured":"Lefere, S. & Tacke, F. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. JHEP Rep. 1, 30\u201343. https:\/\/doi.org\/10.1016\/j.jhepr.2019.02.004 (2019).","journal-title":"JHEP Rep."},{"key":"94401_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073","author":"A Mantovani","year":"2021","unstructured":"Mantovani, A. et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An updated meta-analysis of randomized controlled trials. Metabolites https:\/\/doi.org\/10.3390\/metabo11020073 (2021).","journal-title":"Metabolites"},{"key":"94401_CR15","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X (2016).","journal-title":"Lancet"},{"key":"94401_CR16","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.metabol.2024.155835","volume":"154","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis, M. et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. Metabolism 154, 155835. https:\/\/doi.org\/10.1016\/j.metabol.2024.155835 (2024).","journal-title":"Metabolism"},{"key":"94401_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000329080","volume":"34","author":"Q Yuan","year":"2011","unstructured":"Yuan, Q. et al. Fluorofenidone attenuates tubulointerstitial fibrosis by inhibiting TGF-beta (1)-induced fibroblast activation. Am. J. Nephrol. 34, 181\u2013194. https:\/\/doi.org\/10.1159\/000329080 (2011).","journal-title":"Am. J. Nephrol."},{"key":"94401_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000329419","volume":"88","author":"LH Wang","year":"2011","unstructured":"Wang, L. H. et al. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db\/db mice. Pharmacology 88, 88\u201399. https:\/\/doi.org\/10.1159\/000329419 (2011).","journal-title":"Pharmacology"},{"key":"94401_CR19","doi-asserted-by":"publisher","first-page":"534775","DOI":"10.3389\/fphar.2020.534775","volume":"11","author":"Q Dai","year":"2020","unstructured":"Dai, Q. et al. Fluorofenidone alleviates renal fibrosis by inhibiting necroptosis through RIPK3\/MLKL pathway. Front. Pharmacol. 11, 534775. https:\/\/doi.org\/10.3389\/fphar.2020.534775 (2020).","journal-title":"Front. Pharmacol."},{"key":"94401_CR20","doi-asserted-by":"publisher","first-page":"e21497","DOI":"10.1096\/fj.202002402R","volume":"35","author":"S Tu","year":"2021","unstructured":"Tu, S. et al. Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF-kappaB pathway. FASEB J. 35, e21497. https:\/\/doi.org\/10.1096\/fj.202002402R (2021).","journal-title":"FASEB J."},{"key":"94401_CR21","doi-asserted-by":"publisher","first-page":"G253","DOI":"10.1152\/ajpgi.00471.2012","volume":"306","author":"Y Peng","year":"2014","unstructured":"Peng, Y. et al. Fluorofenidone attenuates hepatic fibrosis by suppressing the proliferation and activation of hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G253-263. https:\/\/doi.org\/10.1152\/ajpgi.00471.2012 (2014).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"94401_CR22","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/jcmm.12898","volume":"20","author":"C Song","year":"2016","unstructured":"Song, C. et al. Fluorofenidone attenuates pulmonary inflammation and fibrosis via inhibiting the activation of NALP3 inflammasome and IL-1beta\/IL-1R1\/MyD88\/NF-kappaB pathway. J. Cell. Mol. Med. 20, 2064\u20132077. https:\/\/doi.org\/10.1111\/jcmm.12898 (2016).","journal-title":"J. Cell. Mol. Med."},{"key":"94401_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejphar.2016.01.006","volume":"773","author":"YH Wu","year":"2016","unstructured":"Wu, Y. H. et al. Fluorofenidone attenuates bleomycin-induced pulmonary fibrosis by inhibiting eukaryotic translation initiation factor 3a (eIF3a) in rats. Eur. J. Pharmacol. 773, 42\u201350. https:\/\/doi.org\/10.1016\/j.ejphar.2016.01.006 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"94401_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/SHK.0000000000001960","volume":"58","author":"C Song","year":"2022","unstructured":"Song, C. et al. Fluorofenidone attenuates pulmonary inflammation and fibrosis by inhibiting the Il-11\/Mek\/Erk Signaling pathway. Shock 58, 137\u2013146. https:\/\/doi.org\/10.1097\/SHK.0000000000001960 (2022).","journal-title":"Shock"},{"key":"94401_CR25","doi-asserted-by":"publisher","first-page":"772031","DOI":"10.3389\/fphar.2021.772031","volume":"12","author":"X Lv","year":"2021","unstructured":"Lv, X. et al. Protective effect of fluorofenidone against acute lung injury through suppressing the MAPK\/NF-kappaB pathway. Front. Pharmacol. 12, 772031. https:\/\/doi.org\/10.3389\/fphar.2021.772031 (2021).","journal-title":"Front. Pharmacol."},{"key":"94401_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.intimp.2010.02.005","volume":"10","author":"Y Tang","year":"2010","unstructured":"Tang, Y. et al. Fluorofenidone protects mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-1beta release. Int. Immunopharmacol. 10, 580\u2013583. https:\/\/doi.org\/10.1016\/j.intimp.2010.02.005 (2010).","journal-title":"Int. Immunopharmacol."},{"key":"94401_CR27","doi-asserted-by":"publisher","first-page":"166556","DOI":"10.1016\/j.bbadis.2022.166556","volume":"1868","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk\/-Egr-1 signaling and Tgfbeta1\/Smad pathway in mice. Biochim. Biophys. Acta Mol. Basis Dis. 1868, 166556. https:\/\/doi.org\/10.1016\/j.bbadis.2022.166556 (2022).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"94401_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.06.012","author":"BL Clifford","year":"2021","unstructured":"Clifford, B. L. et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. https:\/\/doi.org\/10.1016\/j.cmet.2021.06.012 (2021).","journal-title":"Cell Metab."},{"key":"94401_CR29","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","volume":"71","author":"M Trauner","year":"2022","unstructured":"Trauner, M. & Fuchs, C. D. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 71, 194\u2013209. https:\/\/doi.org\/10.1136\/gutjnl-2021-324305 (2022).","journal-title":"Gut"},{"key":"94401_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/eci.12053","volume":"43","author":"Y Peng","year":"2013","unstructured":"Peng, Y. et al. The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways. Eur. J. Clin. Invest. 43, 358\u2013368. https:\/\/doi.org\/10.1111\/eci.12053 (2013).","journal-title":"Eur. J. Clin. Invest."},{"key":"94401_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto, M. et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int. J. Exp. Pathol. 94, 93\u2013103. https:\/\/doi.org\/10.1111\/iep.12008 (2013).","journal-title":"Int. J. Exp. Pathol."},{"key":"94401_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/nu12123886","author":"E Dungubat","year":"2020","unstructured":"Dungubat, E. et al. Effects of caffeine and chlorogenic acid on nonalcoholic steatohepatitis in mice induced by choline-deficient, L-amino acid-defined, high-fat diet. Nutrients https:\/\/doi.org\/10.3390\/nu12123886 (2020).","journal-title":"Nutrients"},{"key":"94401_CR33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.055","author":"O Chavez-Talavera","year":"2017","unstructured":"Chavez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2017.01.055 (2017).","journal-title":"Gastroenterology"},{"key":"94401_CR34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","volume":"19","author":"CD Fuchs","year":"2022","unstructured":"Fuchs, C. D. & Trauner, M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat. Rev. Gastroenterol. Hepatol. 19, 432\u2013450. https:\/\/doi.org\/10.1038\/s41575-021-00566-7 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"94401_CR35","doi-asserted-by":"publisher","first-page":"970292","DOI":"10.3389\/fphys.2022.970292","volume":"13","author":"C Fang","year":"2022","unstructured":"Fang, C. et al. The AMPK pathway in fatty liver disease. Front. Physiol. 13, 970292. https:\/\/doi.org\/10.3389\/fphys.2022.970292 (2022).","journal-title":"Front. Physiol."},{"key":"94401_CR36","doi-asserted-by":"publisher","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4, 100479. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100479 (2022).","journal-title":"JHEP Rep."},{"key":"94401_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710055","author":"CL Chen","year":"2022","unstructured":"Chen, C. L. & Lin, Y. C. Autophagy dysregulation in metabolic associated fatty liver disease: A new therapeutic target. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms231710055 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"94401_CR38","doi-asserted-by":"publisher","first-page":"100973","DOI":"10.1016\/j.mam.2021.100973","volume":"82","author":"H Qian","year":"2021","unstructured":"Qian, H. et al. Autophagy in liver diseases: A review. Mol. Aspects Med. 82, 100973. https:\/\/doi.org\/10.1016\/j.mam.2021.100973 (2021).","journal-title":"Mol. Aspects Med."},{"key":"94401_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","volume":"18","author":"Y Filali-Mouncef","year":"2022","unstructured":"Filali-Mouncef, Y. et al. The menage a trois of autophagy, lipid droplets and liver disease. Autophagy 18, 50\u201372. https:\/\/doi.org\/10.1080\/15548627.2021.1895658 (2022).","journal-title":"Autophagy"},{"key":"94401_CR40","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/ncb2329","volume":"13","author":"MM Mihaylova","year":"2011","unstructured":"Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016\u20131023. https:\/\/doi.org\/10.1038\/ncb2329 (2011).","journal-title":"Nat. Cell Biol."},{"key":"94401_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim, Y. C. & Guan, K. L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest. 125, 25\u201332. https:\/\/doi.org\/10.1172\/JCI73939 (2015).","journal-title":"J. Clin. Invest."},{"key":"94401_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","volume":"292","author":"HH Hu","year":"2018","unstructured":"Hu, H. H. et al. New insights into TGF-beta\/Smad signaling in tissue fibrosis. Chem. Biol. Interact. 292, 76\u201383. https:\/\/doi.org\/10.1016\/j.cbi.2018.07.008 (2018).","journal-title":"Chem. Biol. Interact."},{"key":"94401_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tem.2017.05.004","volume":"28","author":"EA Day","year":"2017","unstructured":"Day, E. A., Ford, R. J. & Steinberg, G. R. AMPK as a therapeutic target for treating metabolic diseases. Trends Endocrinol. Metab. 28, 545\u2013560. https:\/\/doi.org\/10.1016\/j.tem.2017.05.004 (2017).","journal-title":"Trends Endocrinol. Metab."},{"key":"94401_CR44","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1126\/science.aay0542","volume":"367","author":"P Zhao","year":"2020","unstructured":"Zhao, P. et al. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis. Science 367, 652\u2013660. https:\/\/doi.org\/10.1126\/science.aay0542 (2020).","journal-title":"Science"},{"key":"94401_CR45","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1002\/hep.32066","volume":"74","author":"M Hu","year":"2021","unstructured":"Hu, M. et al. Salidroside activates the AMP-activated protein kinase pathway to suppress nonalcoholic steatohepatitis in mice. Hepatology 74, 3056\u20133073. https:\/\/doi.org\/10.1002\/hep.32066 (2021).","journal-title":"Hepatology"},{"key":"94401_CR46","doi-asserted-by":"publisher","first-page":"155200","DOI":"10.1016\/j.metabol.2022.155200","volume":"131","author":"LS Yan","year":"2022","unstructured":"Yan, L. S. et al. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK\/mTOR signaling pathway. Metabolism 131, 155200. https:\/\/doi.org\/10.1016\/j.metabol.2022.155200 (2022).","journal-title":"Metabolism"},{"key":"94401_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","volume":"141","author":"X Zhu","year":"2019","unstructured":"Zhu, X. et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic. Biol. Med. 141, 192\u2013204. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2019.06.019 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"94401_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12967-022-03540-2","volume":"20","author":"R Li","year":"2022","unstructured":"Li, R. et al. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway. J. Transl. Med. 20, 341. https:\/\/doi.org\/10.1186\/s12967-022-03540-2 (2022).","journal-title":"J. Transl. Med."},{"key":"94401_CR49","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1142\/S0192415X20500299","volume":"48","author":"JX Zhang","year":"2020","unstructured":"Zhang, J. X. et al. Corosolic acid attenuates hepatic lipid accumulation and inflammatory response via AMPK\/SREBPs and NF-kappaB\/MAPK signaling pathways. Am. J. Chin. Med. 48, 579\u2013595. https:\/\/doi.org\/10.1142\/S0192415X20500299 (2020).","journal-title":"Am. J. Chin. Med."},{"key":"94401_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115851","author":"T Sugasawa","year":"2021","unstructured":"Sugasawa, T. et al. One week of CDAHFD induces steatohepatitis and mitochondrial dysfunction with oxidative stress in liver. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22115851 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"94401_CR51","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12841","author":"K Matsumoto","year":"2022","unstructured":"Matsumoto, K. et al. Hepatic gene expression and functional changes associated with nonalcoholic steatohepatitis. Mol. Med. Rep. https:\/\/doi.org\/10.3892\/mmr.2022.12841 (2022).","journal-title":"Mol. Med. Rep."},{"key":"94401_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-981-15-0602-4_4","volume":"1206","author":"Y Li","year":"2019","unstructured":"Li, Y. & Chen, Y. AMPK and autophagy. Adv. Exp. Med. Biol. 1206, 85\u2013108. https:\/\/doi.org\/10.1007\/978-981-15-0602-4_4 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"94401_CR53","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/hepr.12282","volume":"44","author":"Y Fukuo","year":"2014","unstructured":"Fukuo, Y. et al. Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease. Hepatol. Res. 44, 1026\u20131036. https:\/\/doi.org\/10.1111\/hepr.12282 (2014).","journal-title":"Hepatol. Res."},{"key":"94401_CR54","doi-asserted-by":"publisher","first-page":"e1179","DOI":"10.1038\/cddis.2014.162","volume":"5","author":"A Gonzalez-Rodriguez","year":"2014","unstructured":"Gonzalez-Rodriguez, A. et al. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 5, e1179. https:\/\/doi.org\/10.1038\/cddis.2014.162 (2014).","journal-title":"Cell Death Dis."},{"key":"94401_CR55","doi-asserted-by":"publisher","first-page":"e930166","DOI":"10.12659\/MSM.930166","volume":"27","author":"F Jiang","year":"2021","unstructured":"Jiang, F. et al. Effect of fluorofenidone against paraquat-induced pulmonary fibrosis based on metabolomics and network pharmacology. Med. Sci. Monit. 27, e930166. https:\/\/doi.org\/10.12659\/MSM.930166 (2021).","journal-title":"Med. Sci. Monit."},{"key":"94401_CR56","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349\u2013364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"94401_CR57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev-pathmechdis-032521-102529","volume":"17","author":"M de Carvalho Ribeiro","year":"2022","unstructured":"de Carvalho Ribeiro, M. & Szabo, G. Role of the inflammasome in liver disease. Annu. Rev. Pathol. 17, 345\u2013365. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-032521-102529 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"94401_CR58","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41574-022-00675-6","volume":"18","author":"E Barreby","year":"2022","unstructured":"Barreby, E., Chen, P. & Aouadi, M. Macrophage functional diversity in NAFLD - more than inflammation. Nat. Rev. Endocrinol. 18, 461\u2013472. https:\/\/doi.org\/10.1038\/s41574-022-00675-6 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"94401_CR59","doi-asserted-by":"publisher","first-page":"708978","DOI":"10.3389\/fimmu.2021.708978","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. Hepatic macrophage as a key player in fatty liver disease. Front. Immunol. 12, 708978. https:\/\/doi.org\/10.3389\/fimmu.2021.708978 (2021).","journal-title":"Front. Immunol."},{"key":"94401_CR60","doi-asserted-by":"publisher","first-page":"6489012","DOI":"10.1155\/2016\/6489012","volume":"2016","author":"X Wan","year":"2016","unstructured":"Wan, X., Xu, C., Yu, C. & Li, Y. Role of NLRP3 inflammasome in the progression of NAFLD to NASH. Can. J. Gastroenterol. Hepatol. 2016, 6489012. https:\/\/doi.org\/10.1155\/2016\/6489012 (2016).","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"94401_CR61","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1111\/liv.12537","volume":"34","author":"T Csak","year":"2014","unstructured":"Csak, T. et al. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis. Liver Int. 34, 1402\u20131413. https:\/\/doi.org\/10.1111\/liv.12537 (2014).","journal-title":"Liver Int."},{"key":"94401_CR62","doi-asserted-by":"publisher","first-page":"e56100","DOI":"10.1371\/journal.pone.0056100","volume":"8","author":"LJ Dixon","year":"2013","unstructured":"Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E. & Nagy, L. E. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS ONE 8, e56100. https:\/\/doi.org\/10.1371\/journal.pone.0056100 (2013).","journal-title":"PLoS ONE"},{"key":"94401_CR63","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","volume":"92","author":"A Wree","year":"2014","unstructured":"Wree, A. et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD. J. Mol. Med. (Berlin) 92, 1069\u20131082. https:\/\/doi.org\/10.1007\/s00109-014-1170-1 (2014).","journal-title":"J. Mol. Med. (Berlin)"},{"key":"94401_CR64","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nm.3798","volume":"21","author":"K Liddiard","year":"2015","unstructured":"Liddiard, K. & Taylor, P. R. Understanding local macrophage phenotypes in disease: shape-shifting macrophages. Nat. Med. 21, 119\u2013120. https:\/\/doi.org\/10.1038\/nm.3798 (2015).","journal-title":"Nat. Med."},{"key":"94401_CR65","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2016.08.024","volume":"151","author":"BA David","year":"2016","unstructured":"David, B. A. et al. Combination of mass cytometry and imaging analysis reveals origin, location, and functional repopulation of liver myeloid cells in mice. Gastroenterology 151, 1176\u20131191. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.024 (2016).","journal-title":"Gastroenterology"},{"key":"94401_CR66","doi-asserted-by":"publisher","first-page":"10321","DOI":"10.1038\/ncomms10321","volume":"7","author":"CL Scott","year":"2016","unstructured":"Scott, C. L. et al. Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. Nat. Commun. 7, 10321. https:\/\/doi.org\/10.1038\/ncomms10321 (2016).","journal-title":"Nat. Commun."},{"key":"94401_CR67","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-0037-1604480","volume":"37","author":"O Krenkel","year":"2017","unstructured":"Krenkel, O. & Tacke, F. Macrophages in nonalcoholic fatty liver disease: A role model of pathogenic immunometabolism. Semin. Liver Dis. 37, 189\u2013197. https:\/\/doi.org\/10.1055\/s-0037-1604480 (2017).","journal-title":"Semin. Liver Dis."},{"key":"94401_CR68","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstrom","year":"2017","unstructured":"Hagstrom, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265\u20131273. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.027 (2017).","journal-title":"J. Hepatol."},{"key":"94401_CR69","doi-asserted-by":"publisher","first-page":"113869","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"S Kumar","year":"2021","unstructured":"Kumar, S., Duan, Q., Wu, R., Harris, E. N. & Su, Q. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv. Drug Deliv. Rev. 176, 113869. https:\/\/doi.org\/10.1016\/j.addr.2021.113869 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"94401_CR70","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","volume":"60","author":"F Tacke","year":"2014","unstructured":"Tacke, F. & Zimmermann, H. W. Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60, 1090\u20131096. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.025 (2014).","journal-title":"J. Hepatol."},{"key":"94401_CR71","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev-pathol-011110-130246","volume":"6","author":"V Hernandez-Gea","year":"2011","unstructured":"Hernandez-Gea, V. & Friedman, S. L. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6, 425\u2013456. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130246 (2011).","journal-title":"Annu. Rev. Pathol."},{"key":"94401_CR72","doi-asserted-by":"publisher","first-page":"W317","DOI":"10.1093\/nar\/gkab447","volume":"49","author":"D Bu","year":"2021","unstructured":"Bu, D. et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 49, W317\u2013W325. https:\/\/doi.org\/10.1093\/nar\/gkab447 (2021).","journal-title":"Nucleic Acids Res."},{"key":"94401_CR73","doi-asserted-by":"publisher","first-page":"683506","DOI":"10.3389\/fmed.2021.683506","volume":"8","author":"C Wu","year":"2021","unstructured":"Wu, C. et al. Hepatic BRD4 is upregulated in liver fibrosis of various etiologies and positively correlated to fibrotic severity. Front. Med. (Lausanne) 8, 683506. https:\/\/doi.org\/10.3389\/fmed.2021.683506 (2021).","journal-title":"Front. Med. (Lausanne)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94401-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94401-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94401-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:54:35Z","timestamp":1742604875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94401-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94401"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94401-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9863"}}